MoonLake Immunotherapeutics
MLTX
$55.65
$0.811.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.22M | -39.94M | -45.60M | -35.39M | -24.27M |
| Total Depreciation and Amortization | 742.00K | 378.00K | 1.30M | 32.50K | 342.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.14M | 1.80M | -269.70K | 1.80M | 1.36M |
| Change in Net Operating Assets | -1.19M | -369.00K | -3.90M | 8.28M | -5.32M |
| Cash from Operations | -54.53M | -38.14M | -48.47M | -25.27M | -27.89M |
| Capital Expenditure | 0.00 | -35.00K | -175.60K | -132.20K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.25M | 56.28M | -147.16M | 58.41M | -87.74M |
| Cash from Investing | 88.25M | 56.25M | -147.33M | 58.28M | -87.74M |
| Total Debt Issued | 0.00 | 73.02M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 100.00K | 150.70K | 91.30K | 0.00 |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 91.80K | 0.00 |
| Cash from Financing | 0.00 | 73.12M | 150.70K | 183.10K | 0.00 |
| Foreign Exchange rate Adjustments | 1.39M | -88.00K | 423.80K | -325.40K | -17.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.12M | 91.14M | -195.23M | 32.87M | -115.65M |